Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px
Document › Details

Veraxa Biotech GmbH. (3/22/22). "Press Release: Torsten Buergermeister Joins Veraxa Biotech GmbH as Chief Financial Officer". Heidelberg.

Organisations Organisation Veraxa Biotech GmbH (DE)
  Group Veraxa Biotech (Group)
  Organisation 2 Molecular Health GmbH (MolecularHealth)
  Group Molecular Health (Group)
Products Product therapeutic antibody
  Product 2 antibody-drug conjugate (ADC)
Persons Person Bürgermeister, Torsten (Veraxa Biotech 202203– CFO before Molecular Health)
  Person 2 Antz, Cristoph (Veraxa Biotech 202106 Managing Director before Acousia Therapeutics + Elara + EMBL Ventures + Abeta)

The new CFO brings extensive experience in finance and business development at life science, pharma and technology companies.

Torsten Buergermeister has been appointed Chief Financial Officer (CFO) of VERAXA Biotech, based in Heidelberg, Germany. Buergermeister joins VERAXA from Molecular Health, an international Precision Medicine company where he had global responsibilities as Senior Vice President of Finance.

“Torsten brings excellent financial managing skills with a very good knowledge of biotech and related capital markets,” said Dr. Christoph Antz, CEO of VERAXA. “We are excited to have him join our management team.”

About VERAXA Biotech

VERAXA’S mission is to tackle two of the biggest challenges in antibody drug development: Antibody discovery and ADC development. The company’s droplet-based microfluidic screening technology and its innovative antibody and protein conjugation technology allows for a rapid generation of antibodies against most complex target molecules and for a target product profile sharpening of existing monoclonal antibody candidates in oncology or precision medicine. VERAXA Biotech GmbH is a fusion of Velabs Therapeutics GmbH and Araxa Biosciences GmbH, both spin-off companies from European Molecular Biology Laboratory (EMBL), Europe’s most renowned institute for life science research and instrument development. VERAXA is a preferred license and cooperation partner of global biotech and pharma industries.

Record changed: 2022-04-05


Picture [iito] No Tracking 650x100px

More documents for Veraxa Biotech (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px

» top